300558 贝达药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.1776.8923.0918.80418.371
总资产报酬率 ROA (%)2.4494.0812.0516.66112.952
投入资产回报率 ROIC (%)2.8694.8282.4527.73714.307

边际利润分析
销售毛利率 (%)83.85783.53288.69492.23392.573
营业利润率 (%)16.91710.9953.98917.61536.394
息税前利润/营业总收入 (%)17.87214.72411.07217.41637.923
净利润/营业总收入 (%)14.40113.5835.25016.90032.139

收益指标分析
经营活动净收益/利润总额(%)95.72875.225-22.02889.13355.824
价值变动净收益/利润总额(%)-2.073-4.244-23.5454.09443.900
营业外收支净额/利润总额(%)-1.52316.147-8.251-1.455-2.101

偿债能力分析
流动比率 (X)0.7000.8460.8231.8614.218
速动比率 (X)0.5080.6650.6461.5313.787
资产负债率 (%)39.13641.49437.32525.2840.208
带息债务/全部投入资本 (%)28.06929.68724.748-1.880-0.986
股东权益/带息债务 (%)246.966229.159292.509-4,701.270-8,857.803
股东权益/负债合计 (%)152.936138.352164.239287.637381.518
利息保障倍数 (X)14.7959.1361.499322.09416.649

营运能力分析
应收账款周转天数 (天)29.82352.74445.61317.75610.456
存货周转天数 (天)242.436311.364445.819497.287418.790